Basic Vencarm Information

• INN (International Nonproprietary Name): Venlafaxine
• Brand Names Available In United Kingdom: Effexor / Effexor XR; Efexor (spelling variation used in the UK and some European countries); Trevilor; Viepax; generic venlafaxine products from Teva, Sandoz, Mylan, Torrent and Aurobindo
• ATC Code: N06AX16
• Forms & Dosages: Immediate‑release tablets 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg; Extended‑release capsules/tablets 37.5 mg, 75 mg, 150 mg
• Manufacturers In United Kingdom: Pfizer (originator brand Effexor/Effexor XR) and multiple generic manufacturers represented in UK pharmacies (Teva, Sandoz, Mylan, Torrent, Aurobindo)
• Registration Status In United Kingdom: Not specified in the supplied data; authorised in the EU under multiple brands and registered in other national databases (check local regulator/SPC for UK specifics)
• OTC / Rx Classification: Prescription (Rx Only)

Latest Research Highlights (UK And EU) — Key Studies 2022–2025

Which recent studies help GPs, psychiatrists and pharmacists choose venlafaxine over other options?

Randomised and observational work in NHS settings from 2022 through mid‑2024 has clarified where SNRIs like venlafaxine sit versus SSRIs and other SNRIs.

Switching to an SNRI after SSRI non‑response has generally shown faster symptom reduction in treatment‑resistant depression cohorts in these studies.

Venlafaxine in particular appears effective where anxiety and depression co‑exist, with several NHS audits reporting clearer improvement in combined anxiety–depression presentations.

Safety signals remain consistent across studies and pharmacovigilance summaries into 2025 reviews: dose‑related hypertension, sexual dysfunction and discontinuation symptoms are the primary concerns.

EU meta‑analyses pooling cohort data show modestly higher odds of remission with venlafaxine versus some SSRIs, but also higher withdrawal rates due to adverse events.

MHRA Yellow Card and EudraVigilance summaries emphasise periodic blood pressure monitoring and highlight hyponatraemia reports in older adults.

Practical product information remains unchanged: ATC N06AX16; immediate‑release tablets 25–100 mg and extended‑release/XR 37.5–150 mg are the common forms used for MDD, GAD, social anxiety disorder and panic disorder.

Clinical Effectiveness In The UK — NHS Treatment Outcomes And Patient Reports

What do NHS audits and patients say about real‑world use of venlafaxine?

In UK practice venlafaxine is commonly started in secondary care and sometimes initiated by GPs following NICE pathways when first‑line SSRIs fail or when anxiety symptoms are prominent.

NHS outcome measures and local audits report meaningful symptom reduction in moderate to severe depression and in panic disorder cohorts treated with venlafaxine.

Some cohorts show faster symptomatic improvement after switching to an SNRI versus a second SSRI, particularly where anxiety is a leading feature.

Patient feedback captured on NHS surveys and Patient.info threads balances benefits and burdens: improved mood and reduced anxiety often noted, but sexual side‑effects and sleep disturbance are frequently reported.

Relapse prevention aligns with standard guidance — treatment is continued for months to years depending on recurrence risk, with maintenance often up to 225 mg/day and in selected cases higher IR dosing.

Data highlights from NHS audits:

• Meaningful symptom reduction in moderate–severe MDD and panic disorder cohorts.
• Faster response in some SSRI‑nonresponder groups when switched to venlafaxine.
• Patient reports emphasise sexual dysfunction and sleep disturbance as the main burdens.

Indications And Expanded Uses — MHRA Approvals And Off‑Label Practice

What is venlafaxine officially licensed for, and when might clinicians use it off‑label?

Authorised indications mirror FDA approvals: major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder in adults.

In UK specialist practice venlafaxine is sometimes used off‑label for refractory anxiety subtypes or complex combined anxiety–depressive states where psychological therapies alone have not sufficed.

Children and adolescents are generally not recommended because of efficacy concerns and suicidality risk in younger patients.

Off‑label Uses (Specialist Settings):

• Refractory mixed anxiety‑depression where SSRI plus talking therapy was insufficient (limited evidence, specialist opinion).
• Complex anxiety subtypes not responding to first‑line IAPT interventions (used with oversight).

Composition And Brand Landscape — Formulations, Manufacturers, UK Naming

Which brands and formulations will you meet on a prescription or at the pharmacy counter?

INN is venlafaxine, ATC N06AX16, available as immediate‑release tablets and extended‑release/XR formulations.

Originator brands and generics are widespread in the UK market, including Effexor/Effexor XR (Pfizer), Efexor as the spelling variant used in the UK, Trevilor, Viepax and generics from Teva, Sandoz, Mylan, Torrent and Aurobindo.

Prescribers commonly write “venlafaxine” on NHS prescriptions, and brand choice can influence pharmacy costs and dispensed product.

Contraindications And Special Precautions — High‑Risk Groups

Who should not take venlafaxine, and which patients need extra monitoring?

Absolute contraindications include hypersensitivity to venlafaxine or any excipient, concurrent MAOI therapy or within 14 days of MAOI discontinuation, and uncontrolled narrow‑angle glaucoma.

Relative contraindications and precautions include recent myocardial infarction, unstable cardiac disease, a history of mania or bipolar disorder, seizure disorders, uncontrolled hypertension and bleeding risk.

Older adults need monitoring for hyponatraemia and blood pressure changes.

Pregnancy and breastfeeding require specialist discussion; abrupt changes should be avoided and risks weighed carefully.

1. Absolute Contraindications: Hypersensitivity; MAOI use within 14 days; uncontrolled narrow‑angle glaucoma.
2. Relative Contraindications / Precautions: Recent MI or unstable heart disease; history of mania or bipolar disorder; seizure disorders; uncontrolled hypertension; bleeding disorders; electrolyte disturbances, especially hyponatraemia in elderly patients.

Advise caution with driving and alcohol consumption until individual response is known.

Dosage Guidelines — Standard NHS Regimens And Adjustments

How is venlafaxine usually started and adjusted in the NHS?

Major Depressive Disorder: IR commonly 75 mg/day divided or XR 75 mg once daily, with maintenance up to 225 mg/day; in selected cases IR doses up to 375 mg/day have been used under specialist supervision.

Generalised Anxiety Disorder: XR 75 mg once daily, maintenance 75–225 mg/day.

Social Anxiety Disorder: XR typically 75 mg once daily.

Panic Disorder: XR often initiated at 37.5 mg once daily and titrated to 75–225 mg/day.

Special Populations:

• Elderly: Start low and titrate slowly; monitor blood pressure and sodium.
• Liver Impairment: Reduce dose by about 50% and monitor closely.
• Renal Impairment (Moderate–Severe): Reduce dose, typically to 25–50% of usual dosing.

Tapering and Switching:

Gradual titration is recommended and slow cross‑tapering should be planned when switching from or to other antidepressants, with a 14‑day washout when stopping MAOIs before starting venlafaxine.

Missed Dose Rule: Take as soon as remembered unless the next dose is near; do not double the dose.

Interactions Overview — Drugs, Food And MHRA Yellow Card Reports

Which drugs and substances cause the most concern when used with venlafaxine?

Major interaction risks include concurrent MAOI use (contraindicated), other serotonergic agents (SSRIs, SNRIs, triptans, tramadol) which increase serotonin syndrome risk, and agents that raise bleeding risk such as anticoagulants, NSAIDs and antiplatelets.

CYP enzyme inhibitors and inducers can alter venlafaxine metabolism and require SPC‑guided checks.

Alcohol may worsen sedation or mood instability and should not be used as a coping strategy.

MHRA Yellow Card reports include raised blood pressure and hyponatraemia among suspected reactions; report any new or unexpected adverse events.

Cultural Perceptions And Patient Habits In The UK

How do UK patients generally view venlafaxine and antidepressant treatment?

UK patient forums such as Patient.info and community threads show pragmatic acceptance of antidepressants when recommended by GPs or IAPT clinicians.

Pharmacists are trusted sources of counselling on side‑effects, dosing and withdrawal issues.

There is a cultural emphasis on combining medication with talking therapies (IAPT/CBT) and on clear informed consent about sexual side‑effects and withdrawal.

Electronic prescriptions and NHS patient portals mean people expect accessible records and easier repeat prescribing.

Community pharmacies (Boots, LloydsPharmacy, Superdrug) are often first points of contact for side‑effect queries and practical advice on blood pressure monitoring and lifestyle measures such as exercise and sleep hygiene.

Availability And Pricing Patterns In The UK — Pharmacies, E‑Prescriptions, Regional Differences

How easy is it to get venlafaxine in the UK and what affects cost?

Venlafaxine is prescription‑only in all markets according to the supplied data, and multiple generics reduce cost pressure in the NHS and community pharmacy settings.

Major chains and community pharmacies dispense venlafaxine from NHS electronic prescriptions and via private clinics where appropriate.

Regional differences influence purchasing behaviour because Scotland, Wales and Northern Ireland usually do not charge NHS prescription fees, unlike England where per‑item charges apply.

Supply routes and cost drivers include NHS prescription, private prescription, and licensed online pharmacy services that dispense against a valid prescription.

Comparable Medicines And Prescribing Preferences — Pros/Cons Checklist

Which medicines are commonly trialled instead of or after venlafaxine, and why?

Main comparators include duloxetine (Cymbalta), desvenlafaxine, and SSRIs such as sertraline, paroxetine and escitalopram.

Pros of Venlafaxine:

• Evidence of efficacy in combined anxiety–depression and some SSRI‑nonresponders.
• Available in both IR and XR formulations for flexible dosing.

Cons of Venlafaxine:

• Dose‑dependent increases in blood pressure.
• Higher rates of sexual dysfunction and discontinuation symptoms compared with many SSRIs.

FAQ — Common NHS Patient Questions

Will venlafaxine make me gain weight?

Weight changes can occur in either direction; some people lose weight and others gain weight.

How quickly does venlafaxine work?

Some patients notice improvement within 2–4 weeks, but full effect may take 6–8 weeks or longer.

Can I stop suddenly?

No — do not stop abruptly; withdrawal can be severe and a supervised taper is recommended.

Will I need blood pressure checks?

Yes — baseline and periodic blood pressure monitoring is recommended, especially at higher doses.

For missed doses: take as soon as remembered unless the next dose is near and do not double doses.

In overdose seek emergency care for symptoms such as tachycardia, seizures or severe drowsiness.

Guidelines For Proper Use — Pharmacist Counselling And NHS Patient Advice

What should pharmacists cover when counselling someone starting venlafaxine?

Counselling points should include what to expect at start‑up, the need for BP monitoring, common sexual side‑effects, and signs of withdrawal to watch for.

Advise patients that XR is usually taken once daily and may be taken with or without food according to the SPC.

Storage instructions: store between 20–25°C, keep in original packaging and out of reach of children.

Switching advice: allow the recommended MAOI washout of 14 days and plan a slow cross‑taper with the prescriber when changing antidepressants.

Signpost urgent resources: NHS 111, IAPT local services, Samaritans for crisis support and MHRA Yellow Card for adverse reaction reporting.

Pharmacist Checklist

Explain dosing and titration; confirm prescription details and brand; advise on BP monitoring and sexual side‑effects; discuss tapering plans; record counselling in patient records.

Patient Leaflet Template

Why you have been prescribed venlafaxine; how to take it; expected time to benefit; common side‑effects and when to call a clinician; emergency information for overdose.

Delivery Across United Kingdom